31 January 2022 - Blue Note Therapeutics, a prescription digital therapeutics company dedicated to easing the burden of cancer and improving outcomes, today announced that the U.S. FDA has granted breakthrough device designation for BNT200.
BNT200 is a first of its kind prescription-only digital therapeutic to treat anxiety and depressive symptoms in adults with acute myeloid leukaemia who are hospitalised for a regimen of high-intensity induction chemotherapy.